2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearanceThe impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Guissou R, Amaratunga C, de Haan F, Tou F, Cheah P, Yerbanga R, Moors E, Dhorda M, Tindana P, Boon W, Dondorp A, Ouédraogo J. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal 2023, 22: 269. PMID: 37705004, PMCID: PMC10498571, DOI: 10.1186/s12936-023-04705-0.Peer-Reviewed Original ResearchConceptsDepth interviewsGroup discussionsNational policy makersDrug marketBurkina FasoFocus group discussionsPolicy publicationsPublic policyCommunity membersFunding systemPolicy makersAfrican countriesPolicyAnti-malarial policyMarket characteristicsAnti-malarial marketInterviewsRepresentative sampleGrey literatureMarketFasoPerspectiveEmergenceTerms of availabilityDiscussion
2022
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activities
2021
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
de Haan F, Bolarinwa O, Guissou R, Tou F, Tindana P, Boon W, Moors E, Cheah P, Dhorda M, Dondorp A, Ouedraogo J, Mokuolu O, Amaratunga C. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? PLOS ONE 2021, 16: e0256567. PMID: 34464398, PMCID: PMC8407563, DOI: 10.1371/journal.pone.0256567.Peer-Reviewed Original ResearchConceptsAfrican countriesTriple artemisinin-based combination therapiesKey actor groupsMarket prospectsBurkina FasoActor groupsInnovation systemRegulatory arrangementsDepth interviewsInternational fundersArtemisinin-based combination therapyProfit motivesQualitative studySoutheast AsiaGroup discussionsCountry levelAfrican countiesCurrent artemisinin-based combination therapiesLarger communityCountriesDrug marketAcceptability issuesBroad implicationsWorld Health OrganizationMarket readiness
2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDaysThe duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalenceIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2019
Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children
Chotsiri P, Zongo I, Milligan P, Compaore Y, Somé A, Chandramohan D, Hanpithakpong W, Nosten F, Greenwood B, Rosenthal P, White N, Ouédraogo J, Tarning J. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nature Communications 2019, 10: 480. PMID: 30696903, PMCID: PMC6351525, DOI: 10.1038/s41467-019-08297-9.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionSmall childrenPlasmodium falciparum malariaHigh transmission seasonLower drug exposureSigmoidal Emax modelHigh transmission periodYoung childrenAlternative regimenFalciparum malariaDose scheduleMonthly dosesOptimal dosingDrug exposurePreventive efficacyTransmission seasonPharmacokinetic parametersBody weightEmax modelMalaria incidenceVulnerable populationsHigh dosageChildrenChemopreventionEvaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima S, Sagara I, Soulama I, Ouedraogo J, Beavogui A, Borghini-Fuhrer I, Khan Y, Djimdé A, Voiriot P. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports 2019, 9: 883. PMID: 30696921, PMCID: PMC6351684, DOI: 10.1038/s41598-018-37113-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyQTc prolongationHeart rate changesCombination therapyVentricular repolarizationQT/QTc interval prolongationEvidence of proarrhythmiaQTc interval prolongationQTc assessmentLethal ventricular arrhythmiasExtent of prolongationMalaria crisisArtemether-lumefantrineInterval prolongationVentricular arrhythmiasAfrican patientsClinical safetyFirst episodeQT intervalHeart rateAntimalarial drugsProlongationQT correctionECG recordingsHigh-quality ECG recording
2018
Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Drugs T, Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo A, Koumare S, Keita M, Camara D, Somé A, Coulibaly A, Traore O, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini M, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore M, Ouattara S, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma E, Thera I, Compaore Y, Sutherland C, Sylla M, Nikiema F, Diallo M, Dicko A, Picot S, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Gil J, Björkman A, Ouedraogo J, Sirima S, Djimde A. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet 2018, 391: 1378-1390. PMID: 29606364, PMCID: PMC5889791, DOI: 10.1016/s0140-6736(18)30291-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyFirst-line artemisinin-based combination therapyArtemether-lumefantrineDay 28Day 42Study drugUncomplicated malariaMalaria episodesEligible participantsIncidence ratePan African Clinical Trials RegistryUncomplicated P falciparum malariaCurrent first-line therapyAfrican Clinical Trials RegistryDeveloping Countries Clinical Trials PartnershipDihydroartemisinin-piperaquine treatmentFirst malaria episodeP falciparum malariaUncomplicated malaria episodesFirst-line therapyHistory of feverClinical Trials RegistryNon-falciparum speciesMild transient elevationUK Medical Research Council
2017
Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Valea I, Sorgho H, Ouédraogo J, Guiguemdé T, Tinto H. Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso. Annals Of Parasitology 2017, 63: 127-131. PMID: 28822205, DOI: 10.17420/ap6302.96.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrine groupsCure rateArtemether-lumefantrineHigh incidenceDifferent artemisinin-based combination therapiesMalaria transmissionPost-treatment prophylactic effectRandomized open-label trialArtemisinin-based combination therapyArtesunate-amodiaquine treatmentHigh seasonal transmissionUncorrected cure ratesOpen-label trialUncomplicated falciparum malariaMerozoite surface protein 1Surface protein 1Antimalarial regimensArtesunate-AmodiaquinePCR adjustmentLabel trialUncomplicated malariaFalciparum malariaMalaria episodesRecurrent parasitaemiaComparison of effectiveness
2016
Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso
Somé A, Sorgho H, Zongo I, Bazié T, Nikiéma F, Sawadogo A, Zongo M, Compaoré Y, Ouédraogo J. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite 2016, 23: 60. PMID: 28004634, PMCID: PMC5178381, DOI: 10.1051/parasite/2016069.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, BacterialAntigens, SurfaceAntimalarialsArtemisininsBurkina FasoChildChild, PreschoolDrug ResistanceDrug Therapy, CombinationHumansInfantMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsYoung AdultConceptsPolymerase chain reactionUncomplicated malariaDrug resistance polymorphismsPfcrt 76TResistance-mediating polymorphismsPrevalence of polymorphismsSymptomatic malaria patientsAntimalarial drug resistanceGlobal malaria controlEmergence of resistancePfmdr1 184FPfmdr1 86YMalaria patientsPfdhps genesBaseline prevalenceCombination therapyHealth centersBlood samplesWestern CambodiaBetter efficacyGene polymorphismsCodon 540Malaria controlDrug resistancePfdhpsA Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms
Ménard D, Khim N, Beghain J, Adegnika A, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos M, Cao J, Chen J, Collet L, Cui L, Thakur G, Dieye A, Djallé D, Dorkenoo M, Eboumbou-Moukoko C, Espino F, Fandeur T, Ferreira-da-Cruz M, Fola A, Fuehrer H, Hassan A, Herrera S, Hongvanthong B, Houzé S, Ibrahim M, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner P, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati J, Ménard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niaré K, Noedl H, Ouédraogo J, Pillai D, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silué K, Sirima S, Sutherland C, Syafruddin D, Tahar R, Tang L, Touré O, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale J, Stokes B, Straimer J, Witkowski B, Fidock D, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. New England Journal Of Medicine 2016, 374: 2453-2464. PMID: 27332904, PMCID: PMC4955562, DOI: 10.1056/nejmoa1513137.Peer-Reviewed Original ResearchConceptsK13 mutationsRing-stage survival assayK13-propeller polymorphismsPlasmodium falciparum resistanceA578S mutationParasite clearanceRare nonsynonymous mutationsFalciparum resistanceAntimalarial resistanceArtemisinin resistanceNationwide surveillanceGlobal burdenSentinel sitesGeographic disparitiesSurvival assaysP. falciparum genesMalariaPropeller domainMajor determinantArtemisininMutationsNonsynonymous mutationsSuch resistancePolymorphismPatientsArtesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valéa I, Sorgho H, Owusu-Dabo E, Ouédraogo J, Guiguemdé T, Tinto H. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE 2016, 11: e0151565. PMID: 27031231, PMCID: PMC4816516, DOI: 10.1371/journal.pone.0151565.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsBurkina FasoChildDrug CombinationsEthanolaminesFemaleFluorenesGene FrequencyGenotypeHost-Parasite InteractionsHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMultivariate AnalysisParasitemiaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsTreatment OutcomeConceptsPfmdr1 allelesTreatment failureArtemether-lumefantrine therapyPfcrt K76TSingle nucleotide polymorphismsRestriction fragment length polymorphism methodFragment length polymorphism methodPotential beneficial effectsLength polymorphism methodArtesunate-AmodiaquineRecurrent parasitaemiaTreatment regimenACT resistanceCombination therapyK76TPfmdr1 geneClinical trialsTreatment outcomesMultivariate analysisDay 0PfcrtMalaria controlBlood spotsBeneficial effectsPolymorphism methodGenomic epidemiology of artemisinin resistant malaria
Amato R, Miotto O, Woodrow C, Almagro-Garcia J, Sinha I, Campino S, Mead D, Drury E, Kekre M, Sanders M, Amambua-Ngwa A, Amaratunga C, Amenga-Etego L, Andrianaranjaka V, Apinjoh T, Ashley E, Auburn S, Awandare G, Baraka V, Barry A, Boni M, Borrmann S, Bousema T, Branch O, Bull P, Chotivanich K, Conway D, Craig A, Day N, Djimdé A, Dolecek C, Dondorp A, Drakeley C, Duffy P, Echeverry D, Egwang T, Fairhurst R, Faiz A, Fanello C, Hien T, Hodgson A, Imwong M, Ishengoma D, Lim P, Lon C, Marfurt J, Marsh K, Mayxay M, Michon P, Mobegi V, Mokuolu O, Montgomery J, Mueller I, Kyaw M, Newton P, Nosten F, Noviyanti R, Nzila A, Ocholla H, Oduro A, Onyamboko M, Ouedraogo J, Phyo A, Plowe C, Price R, Pukrittayakamee S, Randrianarivelojosia M, Ringwald P, Ruiz L, Saunders D, Shayo A, Siba P, Takala-Harrison S, Thanh T, Thathy V, Verra F, Wendler J, White N, Ye H, Cornelius V, Giacomantonio R, Muddyman D, Henrichs C, Malangone C, Jyothi D, Pearson R, Rayner J, McVean G, Rockett K, Miles A, Vauterin P, Jeffery B, Manske M, Stalker J, MacInnis B, Kwiatkowski D. Genomic epidemiology of artemisinin resistant malaria. ELife 2016, 5: e08714. PMID: 26943619, PMCID: PMC4786412, DOI: 10.7554/elife.08714.Peer-Reviewed Original ResearchConceptsKelch13 mutationsArtemisinin-resistant Plasmodium falciparumArtemisinin-resistant malariaResistant Plasmodium falciparumGenomic epidemiologyLarge global surveyPublic health surveillanceArtemisinin resistanceResistant malariaCurrent epidemicHealth surveillancePlasmodium falciparumAmino acid changesEpidemiologyKelch13Non-synonymous mutations
2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilitiesEffectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial
Sondo P, Derra K, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, Valea I, Sorgho H, Owusu-Dabo E, Ouedraogo J, Guiguemde T, Tinto H. Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria Journal 2015, 14: 325. PMID: 26289949, PMCID: PMC4545998, DOI: 10.1186/s12936-015-0843-8.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyOpen-label trialArtemether-lumefantrineYears of ageDrug intakeLabel trialDay 28Randomized open-label trialAge groupsNanoro health districtUncomplicated falciparum malariaMerozoite surface protein 1Primary health centersSurface protein 1Mode of administrationAnti-malarial drugsParents/guardiansParasitological responseUncomplicated malariaAdverse eventsFalciparum malariaMalaria episodesOlder patientsCombination therapyCure rateRandomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
Zongo I, Milligan P, Compaore Y, Some A, Greenwood B, Tarning J, Rosenthal P, Sutherland C, Nosten F, Ouedraogo J. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2015, 59: 4387-4396. PMID: 25918149, PMCID: PMC4505196, DOI: 10.1128/aac.04923-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionAlternative drugsControl groupPrimary outcome measureSeasonal malaria transmissionRandomized noninferiority trialPotential alternative drugDihydroartemisinin-PiperaquinePfdhps mutationsClinical malariaMalaria attacksSulfadoxine-pyrimethamineOdds ratioNoninferiority trialOutcome measuresDHAPQChildren 3Malaria transmissionDrug resistanceAntifolate resistanceChemopreventionChildrenAmodiaquineTrials
2014
Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine
Zongo I, Somé FA, Somda SA, Parikh S, Rouamba N, Rosenthal PJ, Tarning J, Lindegardh N, Nosten F, Ouédraogo JB. Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine. PLOS ONE 2014, 9: e103200. PMID: 25133389, PMCID: PMC4136730, DOI: 10.1371/journal.pone.0103200.Peer-Reviewed Original ResearchConceptsDHA-PQRecurrent malariaDaily dosePlasma concentrationsSingle-arm open-label trialHigher median plasma concentrationsFalciparum malaria treatmentMedian daily dosePharmacokinetics of piperaquineRate of recrudescenceOpen-label trialUncomplicated falciparum malariaMedian plasma concentrationVenous plasma concentrationsSuccessful treatment outcomeDihydroartemisinin-PiperaquineExploratory endpointsParasitological efficacyPiperaquine concentrationsUncomplicated malariaOverall recurrenceYounger patientsFalciparum malariaClinical efficacyCombination therapyPolymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquine